Partial least square and hierarchical clustering in ADMET modeling: Prediction of blood - Brain barrier permeation of α-adrenergic and imidazoline receptor ligands

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 4, 2013, Pages 622-647

  Nikolic, Katarina ^a   Filipic, Slavica ^a   Smoliński, Adam ^b   Kaliszan, Roman ^c   Agbaba, Danica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CENTRAL MINING INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; CARVEDILOL; CLONIDINE; CLOPAMIDE; CLOZAPINE; EFAROXAN; EPHEDRINE; GUANFACINE; HARMAN; HARMINE; IDAZOXAN; IMIDAZOLINE DERIVATIVE; INDAPAMIDE; MAPROTILINE; MIANSERIN; MOXONIDINE; NAPHAZOLINE; OLANZAPINE; OXYMETAZOLINE; PSEUDOEPHEDRINE; RILMENIDINE; TAMSULOSIN; TETRYZOLINE; TIZANIDINE; TRAMAZOLINE; TRIAMTERENE; UNINDEXED DRUG; XYLOMETAZOLINE;

ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ELECTROPHORESIS; CLUSTER ANALYSIS; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; EXTERNAL VALIDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; MATHEMATICAL ANALYSIS; PARTIAL LEAST SQUARES REGRESSION; PH; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE PROPERTY RELATION;

BLOOD-BRAIN BARRIER; CLUSTER ANALYSIS; IMIDAZOLINE RECEPTORS; LEAST-SQUARES ANALYSIS; LIGANDS; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ADRENERGIC, ALPHA;

EID: 84887340023     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3jk5p     Document Type: Article

References (45)

1. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther, 1984; 230:232-236.
2. Tibirica E, Feldman J, Bousquet P. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J Pharmacol Exp Ther, 1988; 244:1062-1066.
3. Ernsberger P. Pharmacology of moxonidine: An I1-imidazoline receptor agonist. J Cardiovasc Pharmacol, 2000; 35:S27-S41.
4. Bousquet P, Feldman J. Drugs acting on imidazoline receptors. A review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection. Drugs, 1999; 58:799-812.
5. Schann S, Greney H, Gasparik V, Dontenwill M, Rascente C, Lacroix G, Monassier L, Bruban V, Feldman J, Ehrhardt JD, Bousquet P. Methylation of imidazoline related compounds leads to loss of α2-adrenoceptor affinity. Synthesis and biological evaluation of selective I1 imidazoline receptor ligands. Bioorg Med Chem, 2012; 20:4710-4715.
6. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. Seeing through a Glass Darkly: Casting Light on Imidazoline I Sites. Trends Pharmacol Sci, 1998; 19: 381-390.
7. Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents, 2006; 4:17-32.
8. Bousquet P, Bricca G, Dontenwill M, Feldman J, Greney H, Belcourt A, Stutzmann J, Tibirica E. From the α2-adrenoceptors to the imidazoline preferring receptors. Fundam Clin Pharmacol, 1992; 6:15S-21S.
9. Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther, 1993; 267:1493-1502.
10. Tesson F, Limon-Boulez I, Urban P, Puype M, Vandekerckhove J, Coupry I, Pompon D, Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem, 1995; 270:9856-9861.
11. Valet P, Tran MA, Damase-Michel C, De Saint-Blanquat G, Dang Tran L, Anglade F, Koenig-Berard E, Montastruc JL. Rilmenidine (S 3341) and the sympatho-adrenal system: Adrenoreceptors, plasma and adrenal catecholamines in dogs. J Auton Pharmacol, 2000; 8:319-326.
12. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther, 1991; 5:967-972.
13. Kline RL, Cechetto DF. Renal effects of rilmenidine in anaesthetized rats: importance of renal nerves. J Pharmacol Exp Ther, 1993; 266:1556-1562.
14. Kimura A, Tyacke RJ, Robinson JJ, Husbands SM, Minchin MCW, Nutt DJ, Hudson AL. Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site. Brain Research 2009; 1279:21-28.
15. Halaris A, Piletz JE. Relevance of Imidazoline Receptors and Agmatine to Psychiatry, A Decade of Progress. Ann NY Acad Sci, 2003; 1009:1-20.
16. Soczewiński E, Wachtmeister CA. The relation between the composition of certain ternary twophase solvent systems and RM values. J Chrom, 1962; 7:311-320.
17. Snyder LR, Dolan JW, Gant JR. Gradient elution in high-performance liquid chromatography: I. Theoretical basis for reversed-phase systems. J Chrom, 1979; 165:3-30.
18. Becke AD. Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys, 1993; 98:5648-5652.
19. Lee C, Yang W, Parr RG, Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B Condens Matter, 1988; 37:785-789.
20. Frisch MJ. et al, Gaussian 98 (Revision A.7) Gaussian, Inc., Pittsburgh PA, 1998.
21. Remko M, Swart M, Bickelhaupt FM. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem, 2006; 14:1715-1728.
22. ChemAxon Marvin 5.5.1.0 program, Budapest, Hungary, 2011. www.chemaxon.com/products.html
23. CS Chem3D Ultra 7.0, Cambridge Soft Corporation, (Property Picker ActiveX Control), 100 Cambridge Park Dr. Cambridge, MA 02140-2317 U.S.A., 2001. http://www.cambridgesoft.com/
24. Dragon 6, TALETE srl, Via V. Pisani, 13-20124 Milano-Italy. http://www.talete.mi.it
25. Parr RG, Yang W, Density-Functional Theory of Atoms and Molecules, Oxford, University Press, New York USA, 1989.
26. Parr RG, Szentpály LV, Liu S. Electrophilicity index. J Am Chem Soc, 1999; 121:1922-1924.
27. ACD/i-Lab Freeware, Advanced Chemistry Development, Inc., Toronto, ON, Canada, 2012, www.acdlabs.com
28. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikstrom C, Wold S. (Eds.) Multi-and Megavariate Data Analysis. Basic Principles and Applications I, 2nd ed., Umetrics Academy, Umeå, Sweden, 2001.
29. Umetrics AB, Umea, Sweden, SIMCA P+ program, Version 12.0.0.0, May 20. 2008, www.umetrics.com
30. Tropsha A. Best Practices for QSAR Model Development, Validation, and Exploitation. Mol Inf, 2010; 29:476-488.
31. Consonni V, Ballabio D, Todeschini R. Comments on the definition of the Q2 parameter for QSAR validation. J Chem Inform Mod, 2009; 49:1669-1678.
32. Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, Smeyers-Verbeke J. In: Handbook of Chemometrics and Qualimetrics: Part A, pp. 519-557, Elsevier, Amsterdam, Netherlands.
33. Vandeginste BGM, Massart DL, Buydens LMC, De Jong S, Lewi PJ, Smeyers-Verbeke J. In: Handbook of Chemometrics and Qualimetrics: Part B, pp. 57-150, Elsevier, Amsterdam, Netherlands.
34. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem, 1988; 31:656-671.
35. Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen JP. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs. Pharmac Research, 1999; 16:1514-1519.
36. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, De Vane CL, Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacol, 2004; 29:551-557.
37. Sills GJ, Kwan P, Butler E, de Lange ECM, van der Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice. Epilepsy Behav, 2002; 3:427-432.
38. Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, Chung SJ. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: Evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos, 2005; 33:440-4488.
39. Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J. Qualitative prediction of blood-brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des, 2011; 25:1095-1106.
40. Consonni V, Todeschini R, Pavan M. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. J Chem Inf Comput Sci, 2002; 42:682-692.
41. Consonni V, Todeschini R, Pavan M, Gramatica P. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 2. Application of the novel 3D molecular descriptors to QSAR/QSPR studies. J Chem Inf Comput Sci, 2002; 42:693-705.
42. Todeschini R, Vighi M, Finizio A, Gramatica P. 3D-modelling and prediction by WHIM descriptors. Part 8. Toxicity and physico-chemical properties of environmental priority chemicals by 2D-TI and 3D-WHIM descriptors. SAR QSAR Environ Res, 1997; 7:173-193.
43. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragmentbased contributions and its application to the prediction of drug transport properties. J Med Chem, 2000; 43:3714-3717.
44. Ivanciuc O. QSAR Comparative Study of Wiener Descriptors for Weighted Molecular Graphs. J Chem Inf Comput Sci, 2000; 40:1412-1422.
45. Lanevskij K, Japertas P, Didziapetris R. Improving the prediction of drug disposition in the brain. Expert Opin Drug Metab Tox, 2013; 9:473-486.